Niranthari Chinniah.

New melanomas and severely dysplastic nevi had been reviewed by a single histopathologist with subspecialty expertise in melanocytic neoplasms, who was unacquainted with the study-group assignments. Assessments for adverse events were performed over the course of the entire 12-month intervention period and for 30 days thereafter. Blood samples were obtained at baseline and at 12 months for full blood counts and for evaluation of electrolyte amounts and renal and liver function. Study End Factors The principal end point was the amount of new, histologically confirmed nonmelanoma skin cancers through the end of the 12-month intervention period.James Larkin, M.D., Ph.D., Paolo A. Ascierto, M.D.D., Ph.D., Victoria Atkinson, M.D., Gabriella Liszkay, M.D., Michele Maio, M.D.D., Lev Demidov, M.D., Daniil Stroyakovskiy, M.D., Luc Thomas, M.D., Ph.D., Luis de la Cruz-Merino, M.D., Caroline Dutriaux, M.D., Claus Garbe, M.D., Mika A. Sovak, M.D., Ph.D., Ilsung Chang, Ph.D., Nicholas Choong, M.D., Stephen P. Hack, M.D., Ph.D., Grant A. McArthur, M.B., B.S., Ph.D., and Antoni Ribas, M.D., Ph.D.: Mixed Cobimetinib and Vemurafenib in BRAF-Mutated Melanoma Approximately 50 percent of metastatic cutaneous melanomas harbor a BRAF V600 mutation, leading to constitutive activation of the mitogen-activated protein kinase pathway.1,2 These discoveries resulted in the development of agents that target this driver mutation specifically.